Current NDC auxiliary source row compounder:232

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 73702-113
Product Ndc: 73702-113
Product Ndc Digits: 73702113
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: Neostigmine Methylsulfate
Proprietary Name Suffix: [empty]
Nonproprietary Name: Neostigmine Methylsulfate
Dosage Form Name: INJECTION
Route Name: INTRAVENOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Wells Pharma of Houston
Establishment Name: Wells Pharma of Houston
Establishment Fei: [empty]
Substance Name: NEOSTIGMINE METHYLSULFATE
Active Ingredients Info: 1 mg/1 mL
History Active Ingredients Raw: NEOSTIGMINE METHYLSULFATE
History Active Ingredients Info Raw: 1 mg/1 mL
History Dosage Raw: INJECTION
Dea Schedule: [empty]
Package Ndc Raw: 73702-113-53
Package Ndc: 73702-113-53
Package Ndc Digits: 7370211353
Package Ndc11: 73702011353
Package Description: 3 mL in 1 SYRINGE (73702-113-53)
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:232
Source Row Number: 232
Source Row Hash: 66d4297621d2d0aaff64189e5b0015ee407cdc824e5b89bb2e00bb3ba623f471
Import Run Id: 20261015T162751Z
Loaded At: 2026-10-15 16:32:20

Exact raw FDA source fields#

{
    "ROUTENAME": "INTRAVENOUS",
    "PRODUCTNDC": "73702-113",
    "DEASCHEDULE": "",
    "LABELERNAME": "Wells Pharma of Houston",
    "SUBSTANCENAME": "NEOSTIGMINE METHYLSULFATE",
    "DOSAGEFORMNAME": "INJECTION",
    "NDCPACKAGECODE": "73702-113-53",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "Neostigmine Methylsulfate",
    "REPORTINGPERIOD": "2025-2",
    "NONPROPRIETARYNAME": "Neostigmine Methylsulfate",
    "PACKAGEDESCRIPTION": "3 mL in 1 SYRINGE (73702-113-53) ",
    "ACTIVEINGREDIENTSINFO": "1 mg/1 mL",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:232
Source Row Number: 232
Status Scope: package
Lookup Ndc: 73702-113-53
Lookup Ndc Digits: 7370211353
Product Ndc: 73702-113
Product Ndc Digits: 73702113
Package Ndc: 73702-113-53
Package Ndc Digits: 7370211353
Package Ndc11: 73702011353
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 66d4297621d2d0aaff64189e5b0015ee407cdc824e5b89bb2e00bb3ba623f471
Import Run Id: 20261015T162751Z
Loaded At: 2026-10-15 16:32:20